Precision Medicine in the Prostate Cancer Care Pathway
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age30-70
SponsorInstitute of Cancer Research, United Kingdom
About this trial
This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.
Eligibility criteria
Qualifiers
Affected with PrCa < 60 years or
Affected with metastatic castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher <70 years
Affected with family history defined as three or more cases any age (FDR or SDR)
FDR diagnosed < 70
Disqualifiers
• WHO performance status 4
Trial design
Treatments tested in this trial
- Prostate cancer risk gene panel
Treatment groups
3,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Institute of Cancer Research, United Kingdom
Lead sponsor
Royal Marsden NHS Foundation Trust
Collaborator
Source ClinicalTrials.gov